Psych Of Aging EXAM 3 (pt.1)

What are the 4 phases of Clinical trials? (plus phase 0)

0) Preclinical

1) Safety + Dosing

2) Safety + Effectiveness

3) Proving Efficacy

4) Post Approval

Define what occurs in each phase of clinical trials (0-4)

0: Preclinical

• Testing drug on animals

1: Safety + Dosing

• Using brave volunteers to test drug out

2: Safety + Efficacy

• Testing drug on LARGER group of pt

• Checking the dosage out

• Lots of INVESTMENT

3: Proving Efficacy

• Test drug on the disease/illness

• VERY LARGE Sample size (international)

• Submit doc to FDA

4: Post-Approval

• FDA-approved drug

• Monitoring Long-term effectiveness

A pharmaceutical company is testing a new compound using mouse models and cultured human skin cells to establish proof of concept. Which phase of clinical trial development does this represent?

• A) Phase 1

• B) Phase 2

• C) Phase 0 (Pre-clinical)

• D) Phase 3

C

A research team is administering an experimental compound to transgenic mice and analyzing its effects on human neuronal cell cultures. This work is BEST classified as which stage of drug development?

• A) Phase I

• B) Phase II

• C) Preclinical

• D) Phase III

C

During a Phase I trial of a new anti-amyloid therapy, investigators are primarily concerned with which of the following?

• A) Whether the drug outperforms a placebo on cognitive measures

• B) Long-term cardiovascular effects after market approval

• C) Route of administration, dosing frequency, and safety

• D) Target engagement with tau proteins

C

A multinational trial enrolling thousands of participants is underway to confirm that a new Alzheimer's drug is both safe and effective compared to placebo. This trial is MOST consistent with which phase?

• A) Phase 1

• B) Phase 2

• C) Phase 3

• D) Phase 4

C

A drug receives FDA approval and enters the market. Researchers continue to monitor patients over several years for previously undetected side effects and long-term outcomes. This surveillance represents which phase?

• A) Phase 1

• B) Phase 2

• C) Phase 3

• D) Phase 4

D

A clinical trial of a novel Alzheimer's therapy uses PET imaging to confirm that the drug is successfully binding to and reducing amyloid plaques in participants' brains. This is MOST consistent with which phase and concept?

• A) Phase I; route of administration

• B) Phase II; target engagement

• C) Phase III; placebo-controlled efficacy

• D) Phase IV; long-term safety

B

Which of the following BEST explains why Phase III Alzheimer's trials are tested against placebo rather than an active comparator?

• A) Placebo trials are less expensive and require fewer participants

• B) FDA regulations require placebo use in all neurology trials

• C) There are currently no approved disease-modifying treatments for AD to compare against

• D) Active comparators interfere with amyloid PET imaging results

C

A Phase III Alzheimer's drug trial enrolls participants across sites in the United States, Europe, and Japan. The trial completes and data is submitted to the FDA. Which of the following BEST describes what happens next?

• A) The drug automatically enters Phase IV surveillance

• B) The FDA reviews the data and considers whether to approve the treatment

• C) The drug returns to Phase II for additional target engagement studies

• D) Researchers begin preclinical animal studies to confirm findings

B

A newly approved Alzheimer's medication has been on the market for 2 years. Neurologists are now tracking patient outcomes over a decade to assess durability of benefit and late-emerging side effects. This represents which phase?

• A) Phase II

• B) Phase III

• C) Phase IV

• D) Preclinical

C

Which of the following correctly matches each trial phase with its PRIMARY focus in the context of Alzheimer's disease research?

• A) Phase I = target engagement; Phase II = dosing route; Phase III = placebo comparison; Phase IV = amyloid clearance

• B) Phase I = animal safety; Phase II = FDA submission; Phase III = long-term outcomes; Phase IV = efficacy

• C) Phase I = route, frequency & safety; Phase II = safety & target engagement; Phase III = efficacy vs. placebo; Phase IV = long-term safety & effectiveness

• D) Phase I = efficacy; Phase II = placebo comparison; Phase III = dosing; Phase IV = target engagement

C

Which is phase 2 known for?

Target Engagement

What is the main difference between Phase 2 + Phase 3?

Phase 2: Safety + Effectiveness

• Target engagement (DOES DRUG TARGET BAD VIRUS?)

• Smaller sample size

Phase 3: Efficacy + meaningfulness of drug (does it target/eliminate what it should)

• Effectiveness BEYOND target engagement

• CLINICAL EFFECTIVENESS

• Meaningful outcomes

• LARGE sample size

A Phase II Alzheimer's trial enrolls 150 participants over 12 months. The primary outcome measure is reduction in amyloid PET signal compared to placebo. Investigators are NOT yet analyzing CDR-SB scores. This design reflects which core principle of Phase II AD trials?

• A) Phase II prioritizes clinical meaningfulness over biomarker changes

• B) Phase II focuses on target engagement rather than clinical effectiveness

• C) Phase II requires large representative samples to detect cognitive changes

• D) Phase II uses CDR-SB as its primary efficacy endpoint

B

Which of the following BEST distinguishes the concept of "efficacy" between Phase II and Phase III Alzheimer's trials?

• A) Phase II measures clinical outcomes; Phase III measures biomarker clearance

• B) Phase II measures target engagement (biomarker reduction); Phase III measures clinically meaningful outcomes like CDR-SB

• C) Both phases use CDR-SB as the primary endpoint, but Phase III adds biomarker data

• D) Phase II and III use identical efficacy endpoints but differ only in sample size

B

An anti-tau compound successfully reduces CSF tau levels by 40% compared to placebo in a Phase II trial with 200 participants over 9 months. A neurologist asks, "But are patients actually doing better cognitively?" Which of the following is the MOST accurate response?

• A) Yes — reduction in tau always correlates directly with cognitive improvement

• B) CDR-SB data from this trial would answer that question, but Phase II is not primarily designed to measure it

• C) Phase II trials are too short to measure tau, so the question is premature

• D) Cognitive outcomes are only measured in preclinical studies, not Phase II

B

Which of the following trial characteristics MOST strongly suggests a Phase III rather than Phase II Alzheimer's trial?

• A) Primary endpoint is amyloid PET reduction; n = 200; duration = 12 months

• B) Primary endpoint is CDR-SB change; n = 1,500; duration = 24 months; international sites

• C) Primary endpoint is tau CSF levels; n = 100; duration = 9 months

• D) Primary endpoint is ARIA monitoring; n = 75; duration = 6 months

B

A colleague argues: "If a drug clears amyloid effectively in Phase II, we can assume it will improve cognition in Phase III." Which of the following is the MOST appropriate critique of this statement?

• A) This is correct — amyloid clearance is a validated surrogate for cognitive benefit

• B) Cognitive improvement is measured in Phase II, making Phase III redundant

• C) This is incorrect because Phase II does not measure amyloid at all

• D) Target engagement in Phase II does not guarantee clinically meaningful outcomes in Phase III; these are distinct measures requiring separate demonstration

D

What are the 4 types of prevention in clinical trials

1) Primordial

2) Primary

3) Secondary

4) Tertiary

What happens in the Primary intervention?

• Drug intervention BEFORE symptoms arise (b/4 disease)

• Cognitively normal

• APOE 4 carriers

Goal:

• Slow down symptoms

• Delay ONSET

What happens in the Secondary intervention?

• Drug intervention AFTER symptoms developed, BUT before SEVERE symptoms

• Mild AD symptoms

Goal:

• SLOW symptoms

• Stop decline completely

Mostly used to TEST DRUGS

What happens in the Secondary intervention?

• Managing & Reducing symptoms

1) Symptom Management

2) Rehab Programs → OT/PT

3) Caregiver Support → Caregiver education

4) Placebos & Randomization

Which intervention phase is mostly used to test drugs?

Secondary

A clinical trial enrolls cognitively normal adults with no biomarker evidence of amyloid accumulation and no symptoms of cognitive decline. The intervention aims to prevent the disease process from ever beginning. This BEST represents which type of prevention?

• A) Secondary prevention

• B) Tertiary prevention

• C) Primary prevention

• D) Indicated prevention

C

A 58-year-old APOE ε4 carrier with a strong family history of AD has a CDR Global of 0 and a negative amyloid PET scan. She is enrolled in an anti-amyloid drug trial. This BEST represents which type of prevention?

• A) Secondary prevention

• B) Tertiary prevention

• C) Primary prevention

• D) Indicated prevention

C

Which of the following BEST distinguishes secondary prevention from primary prevention in AD trials?

• A) Secondary prevention targets APOE ε4 carriers; primary prevention targets all comers

• B) Secondary prevention begins after the disease process has started but before significant symptoms; primary prevention begins before any disease process

• C) Secondary prevention uses placebo; primary prevention does not

• D) Secondary prevention targets tau; primary prevention targets amyloid

B

A clinical trial enrolls participants with CDR Global scores of 0.5–1 who have confirmed amyloid pathology on PET imaging. The trial's best-case goal is to completely halt cognitive decline. This MOST closely represents which prevention type?

• A) Primary prevention

• B) Secondary prevention

• C) Tertiary prevention

• D) Preclinical prevention

B

Leqembi (lecanemab) and Kisunla (donanemab) received FDA approval based on Phase III trials. Based on their trial populations and goals, these drugs are BEST classified under which prevention paradigm?

• A) Primary prevention — targeting cognitively normal at-risk individuals

• B) Tertiary prevention — managing symptoms in moderate-to-severe AD

• C) Secondary prevention — intervening after pathology begins but before significant symptoms

• D) Preclinical prevention — targeting amyloid before any accumulation occurs

C

A hospital system launches a new program for patients with moderate-to-severe AD that includes occupational therapy, caregiver education workshops, and cognitive rehabilitation. No disease-modifying drug is being tested. This BEST represents which type of prevention?

• A) Primary prevention

• B) Secondary prevention

• C) Tertiary prevention

• D) Phase IV post-approval surveillance

C

Regarding the use of placebos and randomization in tertiary prevention trials, which of the following is MOST accurate?

• A) Neither placebos nor randomization are used in tertiary prevention trials

• B) Placebos are standard in both drug and behavioral tertiary trials; randomization is rare

• C) Placebos are commonly used in drug studies but are harder to implement in behavioral studies; randomization is used in both

• D) Randomization is only used in primary and secondary prevention trials

C

Rank the following three participants from EARLIEST to LATEST stage of AD prevention trial eligibility:

• Patient A: CDR = 1, amyloid positive, mild memory complaints

• Patient B: CDR = 0, amyloid negative, APOE ε4 carrier

• Patient C: CDR = 2, established AD diagnosis, enrolled in a caregiver support trial

• A) A → B → C

• B) C → A → B

• C) B → A → C

• D) B → C → A

C

A neurologist states: "Most AD trials conducted to date have been primary prevention trials." Is this accurate?

• A) Yes — primary prevention is the focus because amyloid changes first

• B) Yes — APOE ε4 screening makes primary prevention trials the easiest to run

• C) No — most AD trials to date have been secondary prevention trials

• D) No — most AD trials to date have been tertiary prevention trials focused on symptom management

C